Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

Takeda misleadingly implied generic losartan was a black triangle medicine in ARB heart failure ad (AUTH/2367/10/10)

A two-page Amias ad compared ARBs in heart failure and marked losartan as a black triangle drug. PMCPA…

8 Mar 2026

AUTH/2055/10/07: UCB Pharma advertorial in The Times supplement promoted POMs to the public (Keppra, Neupro)

UCB voluntarily admitted a paid advertorial in a Parkinson’s Disease supplement distributed with The Times that named Keppra…

8 Mar 2026

Astellas breached Clause 7.2 after Qutenza β€˜consensus statement’ insert implied independent/NICE-backed positioning

A Qutenza journal insert styled as a β€˜consensus statement’ and β€˜adapted from NICE’ was ruled misleading: funding/organisation by…

8 Mar 2026

AUTH/2572/1/13: Ex-employee v AstraZeneca – Seroquel investor presentations and weight-gain claims (No breach)

Ex-employee alleged archived investor presentations made false/imbalanced claims about Seroquel and weight gain. Panel and Appeal Board ruled…

8 Mar 2026

Pierre Fabre voluntary admission: uncertified sales briefing materials and pipeline promotion (AUTH/3012/1/18)

Pierre Fabre admitted multiple ABPI Code breaches after using and emailing uncertified cycle-meeting materials for Toviaz, including misleading…

8 Mar 2026

AUTH/2672/11/13: Member of the public v Merck Sharp & Dohme (clinical trial disclosure – Brinavess, Sycrest, Victrelis) – No breach

A member of the public alleged MSD failed to disclose clinical trial results on time for Brinavess, Sycrest…

8 Mar 2026

AUTH/2876/9/16: Health professional v AbbVie (Humira) – β€˜Fast symptom relief’ claim in journal ad (No breach)

A health professional challenged AbbVie’s Humira ad claim β€œFast symptom relief from week 1 (CD) and week 2…

8 Mar 2026

AUTH/2961/6/17: Indivior v Martindale β€” Espranor website promoted to the public and β€œno diversion/instant disintegration” claims ruled misleading

Martindale’s Espranor launch materials (open website, detail aids, patient leaflet) were ruled to promote a POM to the…

8 Mar 2026

AUTH/1967/2/07: PCT prescribing lead v Novartis β€” alleged claim that Exforge was PCT-endorsed (No breach)

A PCT complained a Novartis rep said Exforge was endorsed by the PCT. Evidence suggested a misunderstanding between…

8 Mar 2026

AUTH/2967/8/17 – Consultant v Shire: Omission of prescribing information and other obligatory information (No breach / Out of scope)

PMCPA case AUTH/2967/8/17 (Consultant v Shire). Allegation: omission of prescribing and obligatory information. Outcome: no breach; matter found…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training